Science minister lobbies health department over AstraZeneca drugBMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f368 (Published 17 January 2013) Cite this as: BMJ 2013;346:f368
- Andrew Jack
- 1Financial Times
Government ministers are stepping up efforts to boost NHS prescriptions of recommended new drugs made by companies with a significant presence in the United Kingdom.
David Willetts, the science minister, has raised concerns with his counterparts at the Department of Health for England over the low adoption of new drugs that have been endorsed as safe, effective, and cost effective, including AstraZeneca’s antiplatelet drug ticagrelor (marketed as Brilique).
The action comes after growing complaints from the drug industry that doctors are ignoring positive recommendations on its drugs made by the National Institute for Health and Clinical Excellence (NICE), …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial